Apoha bets molecular behaviour must be measured, not simulated; raises $36M

Deeptech platform selling VIBE readouts: pinhead-sized samples suspended in liquid are stressed, and the resulting wave patterns yield 1,000+ empirical behaviour descriptors per molecule in minutes.

Molecular behaviour under real-world conditions is a data class that cannot be scraped or simulated — only measured — and owning that measurement platform is the moat.

$36M Series A led by Singular with Draper Associates; earlier seed from Redalpine, Seedcamp, Wilbe, Nucleus; Innovate UK grant

CEO Shamit Shrivastava began in 2008 researching boundary physics the Hodgkin-Huxley nerve model left open, finding liquid interfaces carry measurable records of molecular behaviour; the discovery made Scientific American's '13 Discoveries That Could Change Everything' in 2018. He co-founded Apoha in London in 2021 with Anshika Srivastava, a former Goldman Sachs Executive Director.

Spent five years in stealth building the VIBE measurement platform and amassing 60+ patents across hardware, software, data and AI models, signing commercial partners including Boehringer Ingelheim. Emerged 2026-06-03 at SXSW London with a $36M round.

The moat is physical: the behaviour data 'cannot be scraped from the internet, synthesised, or retrofitted from existing assays — it has to be measured.'

Fifteen years of prior science and 60+ patents make the platform hard to replicate quickly.

Pharma failure costs are enormous, so a readout that kills bad candidates early pays for itself.

The same measurement generalises across drugs, food and materials, widening the market without new science.

If the data you need does not exist anywhere, building the instrument that creates it is slower than software but produces a moat competitors cannot download.

As of 2026-06-03, Apoha is deploying the Series A to build 'Liquid State Intelligence' into a foundational data class across biologics, food and materials, with commercial partnerships running at Boehringer Ingelheim, Ethris, THIS and Somru BioSciences.